NCT02292758 - Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2014

Primary Completion Date

March 20, 2019

Study Completion Date

September 27, 2019

Conditions

Colorectal AdenocarcinomaRAS Wild TypeStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7

Interventions

BIOLOGICAL

Bevacizumab

Given IV

BIOLOGICAL

Cetuximab

Given IV

DRUG

Irinotecan

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo

Given IV

Trial Locations (13)

13210

State University of New York Upstate Medical University, Syracuse

48106

Michigan Cancer Research Consortium NCORP, Ann Arbor

51101

Siouxland Regional Cancer Center, Sioux City

54301

Saint Vincent Regional Cancer Center CCOP, Green Bay

55905

Mayo Clinic, Rochester

63131

Missouri Baptist Medical Center, St Louis

64507

Heartland Regional Medical Center, Saint Joseph

67214

Cancer Center of Kansas - Wichita, Wichita

70121

Ochsner Medical Center Jefferson, New Orleans

83712

Saint Luke's Mountain States Tumor Institute, Boise

85259

Mayo Clinic in Arizona, Scottsdale

02215

Dana-Farber Cancer Institute, Boston

03106

New Hampshire Oncology Hematology PA-Hooksett, Hooksett

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER